ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Regulation FD Disclosure

ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

Abbott Ireland Financing DAC, a wholly-owned subsidiary of Abbott Laboratories (“Abbott”), intends to offer senior unsecured notes in an offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), subject to market and other conditions. Abbott will fully and irrevocably guarantee the notes on a senior unsecured basis. Abbott intends to use the net proceeds from the offering of the notes to refinance all or portions of Abbott’s outstanding 2.00% Notes due 2020, 4.125% Notes due 2020, 3.25% Notes due 2023, 3.4% Notes due 2023, and 3.75% Notes due 2026, and for fees, expenses, and other costs associated therewith.

The notes have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or exemption from registration under the U.S. Securities Act. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy any notes in the United States.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, or incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in any such filing.

Forward-Looking Statements

Some statements in this Current Report on Form8-K may be “forward-looking statements” for purposes of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “forecasts,” variations of these words, and similar expressions are intended to identify these forward-looking statements. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed under Item1A. “Risk Factors” in Abbott’s most recent Annual Report on Form10-K and its subsequent Quarterly Reports on Form10-Q. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


About ABBOTT LABORATORIES (NYSE:ABT)

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.